Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07519772 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)

Study acronym: WaveSpan-008
StatusRecruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary endpoint removed 5 → 4 primary endpoints
See other at-risk trials from Merck (MSD)

Record History

  1. Trial sites expanded: 41 → 46 locations
  2. Study sites: 41 to 43
  3. Study sites: 40 to 41
  4. Lead sponsor: Merck Sharp & Dohme LLC to Merck Sharp & Dohme LLC Study sites: 39 to 40 · Eligibility criteria expanded, about 23 words · Secondary endpoints: details revised at 3 of 8 entries Show 3 more changesShow less
    • Study sites: 39 to 40
    • Eligibility criteria expanded, about 23 words
    • Secondary endpoints: details revised at 3 of 8 entries
  5. Study sites: 37 to 39v15
Show 2 earlier versionsHide 2 earlier versions
  1. Study sites: 35 to 37v14
  2. Study sites: 34 to 35v13
  1. Trial sites expanded: 30 → 34 locationsv12
  2. Primary endpoint(s) modified Enrollment increased: 200 → 280 participants · Trial sites expanded: 22 → 30 locations · Secondary endpoints revised (8)v11 Show 3 more changesShow less
    • Enrollment increased: 200 → 280 participants
    • Trial sites expanded: 22 → 30 locations
    • Secondary endpoints revised (8)

    See this version in full on ClinicalTrials.gov ↗

  3. Study sites: 21 to 22v10
  4. Trial sites expanded: 18 → 21 locationsv9
  5. Trial sites expanded: 13 → 18 locationsv8
  6. Trial sites expanded: 8 → 13 locationsv7
  7. Trial sites expanded: 4 → 8 locationsv6
  8. Primary completion pushed from Jan 20, 2030 to Jul 1, 2030 Completion pushed from Oct 21, 2030 to Apr 1, 2031v5 Show 1 more changeShow less
    • Completion pushed from Oct 21, 2030 to Apr 1, 2031
  9. Study sites: 3 to 4v4
  10. Study sites: 1 to 3v3
  11. Recruitment opened Study sites: 0 to 1 · Start date changed from estimate of May 7, 2026 to May 3, 2026v2 Show 2 more changesShow less
    • Study sites: 0 to 1
    • Start date changed from estimate of May 7, 2026 to May 3, 2026
  12. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Merck (MSD)
407 trials monitored
See 29 trials at risk
Non-Hodgkin Lymphoma
1,517 trials monitored
See 84 trials at risk
DLBCL
650 trials monitored
See 38 trials at risk
Follicular Lymphoma
313 trials monitored
See 26 trials at risk
Researchers are looking for new ways to treat 2 types of non-Hodgkin lymphoma (NHL) called follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL). FL is a slow-growing type of NHL. DLBCL is a fast-growing type of NHL. NHL is a cancer in the lymphatic system that causes swollen lymph nodes. The lymphatic system is part of the immune system. In this study, researchers want to learn if MK-1045 can treat FL and DLBCL. MK-1045 is a study treatment that is an immunotherapy, which helps the immune system fight cancer. The goals of this study are to learn how safe MK-1045 is and if people tolerate it. Researchers also want to see if FL and DLBCL respond (the cancer gets smaller or goes away) to treatment.
Trial Details
NCT Number NCT07519772
Lead Sponsor Merck Sharp & Dohme LLC
Conditions Lymphoma, Non-Hodgkin, Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse
Enrollment 280 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov